For example, the drug mesalazine, used to treat inflammatory bowel disease but with an apoptosis-inducing and chemopreventative effect in colon cancer (Bus et al., 1999; Ishikawa et al., 2021); DTI-Voodoo predicts mesalazine to interact with five proteins with PHD-type zinc finger domain: BRPF1, TRIM33, BAZ1A, RSF1 and DPF2. Here, BRPF1 is linked to inflammatory bowel disease.